Artiva Biotherapeutics (ARTV) 24th Annual Needham Virtual Healthcare Conference summary

Market and regulatory environment

• Recent FDA leadership changes provide some comfort, with an insider taking over Peter Marks's role.

• Layoffs at the FDA are not expected to impact reviewers, but ongoing market volatility is being closely watched.

• Company is well-capitalized, with $185 million in cash, providing runway through 2026.

• Focus remains on execution and demonstrating compelling therapy despite uncertain market conditions.

Technology and clinical focus

• Lead product, AlloNK, is an off-the-shelf, cryopreserved allogeneic NK cell therapy targeting B cell depletion in autoimmune diseases.

• Therapy is designed for ease of use, with bedside thawing and a short IV push, making it suitable for community settings.

• Two ongoing trials: a company-sponsored trial in academic centers and an investigator-initiated trial in a community setting.

• Indications under exploration include lupus, rheumatoid arthritis, and others.

Manufacturing and scalability

• AlloNK manufacturing uses umbilical cord units, enabling production of over 4,000 vials per unit, each with 1 billion cells.

• Process is mature and scalable, with costs projected at $1,000 or less per vial, significantly lower than auto CAR-T.

• Non-genetically engineered approach avoids yield loss and long-term patient monitoring required for engineered cells.

• Manufacturing process benefits from 15 years of development experience from parent company GC Cell.